Loading clinical trials...

AZD7268 Safety and Tolerability Study | Clinical Trials | Clareo Health

COMPLETEDPHASE2

AZD7268 Safety and Tolerability Study

A Phase II, Multi-center, Randomized, Double-bind, Double-dummy, Active and Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of AZD7268 in Patients With Major Depressive Disorder

NCT01020799•AstraZeneca

View on ClinicalTrials.gov

Summary

The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Provision of signed, written, and dated Informed Consent prior to any study specific procedures
•Documented primary clinical diagnosis meeting criteria from the DSM-IV, Text Revision (APA 2000) for any of the following:
•296.2x Major Depressive Disorder, Single Episode, or
•296.3x Major Depressive Disorder, Recurrent

Exclusion Criteria

•Patients with a secondary DSM-IV Axis I disorder other than GAD or social anxiety disorder (as assessed by MINI), provided the primary diagnosis is MDD. This diagnosis should have been made at least 6 months before enrollment
•Patients with a diagnosis of DSM-IV Axis II disorder which has a major impact on the patient's current psychiatric status
•Patients whose current episode of depression started less than 4 weeks before enrollment

Locations (17)

Research Site

Birmingham, Alabama, United States

Research Site

Garden Grove, California, United States

Research Site

San Diego, California, United States

Research Site

New Haven, Connecticut, United States

Research Site

Bradenton, Florida, United States

Research Site

Jacksonville, Florida, United States

Research Site

Atlanta, Georgia, United States

Research Site

Rockville, Maryland, United States

Research Site

Cedarhurst, New York, United States

Research Site

New York, New York, United States

Key Dates

Start Date

November 1, 2009

Primary Completion Date

April 1, 2010

Completion Date

April 1, 2010

Last Updated

April 17, 2012

Enrollment

247

ACTUAL participants

Conditions

Major Depressive Disorder

Interventions

AZD7268

DRUG

Escitalopram

DRUG

Placebo capsules

DRUG

Placebo tablets

DRUG

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329

Major Depressive Disorder

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 17, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

AZD7268 Safety and Tolerability Study

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

University of Iowa Interventional Psychiatry Service Patient Registry

A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male Adults